Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (-)-Rolipram. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 19/20 | 1.00 |
| ▸ | PDE4B known ✓ | Q07343 | 12/20 | 1.00 |
| ▸ | PDE4C known ✓ | Q08493 | 11/20 | 1.00 |
| ▸ | PDE4D known ✓ | Q08499 | 11/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | VEGFA | P15692 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | CREBBP | Q92793 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | PDE5A | O76074 | 1/20 | 1.00 |
| ▸ | TNF | P01375 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PDE1A | P54750 | 1/20 | 1.00 |
| ▸ | PDE1B | Q01064 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| S-Rolipram SCHEMBL5321568 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Rolipram SCHEMBL29360376 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| (-)-Rolipram SCHEMBL29598924 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Rolipram SCHEMBL27930 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| S-Rolipram SCHEMBL29475409 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Rolipram SCHEMBL3719855 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| SCHEMBL3544304 | 0.99 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Rolipram SCHEMBL28973411 | 0.99 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Rolipram SCHEMBL15208132 | 0.99 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| SCHEMBL3554826 | 0.99 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119303086-A | Pharmaceutical composition for treating autism | 斯塔利克拉股份有限公司 | 2025-01-14 | — | — | CN | claimed |
| EP-3498297-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | STALICLA S A (CH) | 2023-06-21 | — | — | EP | claimed |
| US-11439627-B2 | Pharmaceutical composition for the treatment of autism | Stalicla S.A. (CH) | 2022-09-13 | — | — | US | claimed |
| US-20220003753-A1 | METABOLIC PROFILING FOR THE DIAGNOSIS OF A SUBSET OF IDIOPATHIC AUTISM SPECTRUM DISORDER PATIENTS, ADS PHENOTYPE 1 | STALICLA SA (CH) | 2022-01-06 | — | — | US | claimed |
| EP-3877540-A1 | METABOLIC PROFILING FOR THE DIAGNOSIS OF A SUBSET OF IDIOPATHIC AUTISM SPECTRUM DISORDER PATIENTS, ASD PHENOTYPE 1 | Stalicla S.A. (CH) | 2021-09-15 | — | — | EP | claimed |
| CN-113166811-A | Metabolic profiling for diagnosing subtype ASD phenotype 1 in patients with idiopathic autism spectrum disorders | 斯大利卡拉公司 | 2021-07-23 | — | — | CN | claimed |
| US-20210154177-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | Stalicla S.A. (CH) | 2021-05-27 | — | — | US | claimed |
| US-20210145803-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | Stalicla S.A. (CH) | 2021-05-20 | — | — | US | claimed |
| EP-3498297-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | Stalicla S.A. (CH) | 2019-06-19 | — | — | EP | claimed |
| CN-109821019-A | Pharmaceutical composition for treating autism | 斯塔利克拉股份有限公司 | 2019-05-31 | — | — | CN | claimed |
| US-20190134011-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | Stalicla S.A. (CH) | 2019-05-09 | — | — | US | claimed |
| US-20040081682-A1 | Transdermal system (tds) that contain inhibitors of phosphodiesterase lV | NEUROBIOTEC GMBH (DE) | 2004-04-29 | — | — | US | claimed |
| EP-1343484-A2 | TRANSDERMAL SYSTEMS (TDS) THAT CONTAIN INHIBITORS OF PHOSPHODIESTERASE IV | Günther, Clemens (DE) | 2003-09-17 | — | — | EP | claimed |
| WO-2002049606-A2 | TRANSDERMAL SYSTEMS (TDS) THAT CONTAIN INHIBITORS OF PHOSPHODIESTERASE IV | GUENTHER CLEMENS (DE) | 2002-06-27 | — | — | WO | claimed |
| WO-2026102437-A1 | METHODS OF TREATING FRAGILE X SYNDROME USING PDE4 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2026-05-15 | — | — | WO | disclosed |
| US-12474327-B2 | Metabolic profiling for the diagnosis of a subset of idiopathic autism spectrum disorder patients, ADS Phenotype 1 | STALICLA SA (CH) | 2025-11-18 | — | — | US | disclosed |
| WO-2024254483-A9 | GENERATING POPULATIONS OF HUMAN BLOOD AND BLOOD VESSEL PROGENITORS FROM PLURIPOTENT STEM CELLS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-11-06 | — | — | WO | disclosed |
| EP-0752853-A1 | HUMAN BRAIN PHOSPHODIESTERASE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-01-15 | — | — | EP | disclosed |
| WO-1994020079-A1 | HUMAN BRAIN PHOSPHODIESTERASE | SMITHKLINE BEECHAM CORPORATION (US) | 1994-09-15 | — | — | WO | disclosed |
| WO-1993007141-A1 | HETEROCYCLIC 3-PHENYLPYRROLIDIN-2-ONES, THEIR PREPARATION AND USE FOR THE MANUFACTURE OF A MEDICAMENT FOR INHIBITING TUMOR NECROSIS FACTOR PRODUCTION | SMITHKLINE BEECHAM CORPORATION (US) | 1993-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040081682-A1 | Transdermal system (tds) that contain inhibitors of phosphodiesterase lV | PDE12, PDE3B, PDE5A | PDE4A 6/4885PDE4B 10/4885PDE4C 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.